AU2017302611B2 - GPR156 variants and uses thereof - Google Patents

GPR156 variants and uses thereof Download PDF

Info

Publication number
AU2017302611B2
AU2017302611B2 AU2017302611A AU2017302611A AU2017302611B2 AU 2017302611 B2 AU2017302611 B2 AU 2017302611B2 AU 2017302611 A AU2017302611 A AU 2017302611A AU 2017302611 A AU2017302611 A AU 2017302611A AU 2017302611 B2 AU2017302611 B2 AU 2017302611B2
Authority
AU
Australia
Prior art keywords
seq
nucleic acid
ser
gpr156
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017302611A
Other languages
English (en)
Other versions
AU2017302611A1 (en
Inventor
Claudia GONZAGA-JAUREGUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017302611A1 publication Critical patent/AU2017302611A1/en
Application granted granted Critical
Publication of AU2017302611B2 publication Critical patent/AU2017302611B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
AU2017302611A 2016-07-28 2017-07-28 GPR156 variants and uses thereof Active AU2017302611B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
US62/367,973 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (2)

Publication Number Publication Date
AU2017302611A1 AU2017302611A1 (en) 2019-03-14
AU2017302611B2 true AU2017302611B2 (en) 2021-12-09

Family

ID=59649989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017302611A Active AU2017302611B2 (en) 2016-07-28 2017-07-28 GPR156 variants and uses thereof

Country Status (13)

Country Link
US (4) US10266582B2 (enExample)
EP (2) EP4230648A3 (enExample)
JP (2) JP7556688B2 (enExample)
KR (2) KR102661616B1 (enExample)
CN (1) CN109563516B (enExample)
AU (1) AU2017302611B2 (enExample)
CA (1) CA3032124A1 (enExample)
DK (1) DK3491014T5 (enExample)
IL (1) IL264473A (enExample)
MX (2) MX2019001084A (enExample)
NZ (1) NZ751010A (enExample)
SG (1) SG11201900738YA (enExample)
WO (1) WO2018022967A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도
CA3074652A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020150426A1 (en) * 2019-01-17 2020-07-23 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
EP0879241A4 (en) 1995-11-21 2000-04-19 Icn Pharmaceuticals INHIBITION OF TUMOR GROWTH BY ANTISENSE OLIGONUCLEOTIDES FOR IL-8 AND THE IL-8 RECEPTOR
EP1007655A1 (en) 1996-02-15 2000-06-14 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
AU2001255397A1 (en) * 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
AU2013262709A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
SI3401400T1 (sl) 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
BR112018012744A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método de fabricação de um anel vaginal
KR102661616B1 (ko) * 2016-07-28 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 Gpr156 변이체 및 이들의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Human TNFRSF11B gene ASO probe, SEQ ID NO: 11.", Geneseq, (2001-04-18), Database accession no. AAF69955, URL: EBI & WO2001/04137 A1 *
"JP 2015518712-A/41866: COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION.", EMBL, (2015-01-09), Database accession no. LX000688, URL: EBI & JP201551872 *
"SubName: Full=G protein-coupled receptor 156 {ECO:0000313Ensembl:ENSCPOP00000019815};", UniProt, (2012-02-22), Database accession no. H0WA05, URL: EBI *
"UDP glycosyltransferase 1 (UGT1A1) allele-specific oligonucleotide #59.", Geneseq, (2002-03-12), Database accession no. AAS99192, URL: EBI & WO2001/79230 A2 *
CATAPANO ET AL, "G protein-coupled receptors in major psychiatric disorders", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, (2007-03-28), vol. 1768, no. 4, pages 976 - 993 *

Also Published As

Publication number Publication date
IL264473A (en) 2019-02-28
CN109563516B (zh) 2023-10-27
DK3491014T3 (da) 2023-05-30
DK3491014T5 (da) 2024-09-02
US11155598B2 (en) 2021-10-26
NZ751010A (en) 2024-11-29
MX2024013403A (es) 2024-12-06
KR20240027874A (ko) 2024-03-04
EP4230648A2 (en) 2023-08-23
EP4230648A3 (en) 2023-10-18
CA3032124A1 (en) 2018-02-01
CN109563516A (zh) 2019-04-02
US20220073589A1 (en) 2022-03-10
US10562953B2 (en) 2020-02-18
JP2019527229A (ja) 2019-09-26
JP7556688B2 (ja) 2024-09-26
KR20190034532A (ko) 2019-04-02
US20190202891A1 (en) 2019-07-04
JP2023071704A (ja) 2023-05-23
EP3491014B1 (en) 2023-04-05
WO2018022967A1 (en) 2018-02-01
KR102661616B1 (ko) 2024-04-30
SG11201900738YA (en) 2019-02-27
AU2017302611A1 (en) 2019-03-14
US10266582B2 (en) 2019-04-23
MX2019001084A (es) 2019-06-10
EP3491014A1 (en) 2019-06-05
US20200231651A1 (en) 2020-07-23
US20180030114A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CN114555621B (zh) 键修饰的寡聚化合物及其用途
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
CN107941681B (zh) 鉴定生物样品中定量细胞组成的方法
CN113853437A (zh) 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
AU2017302611B2 (en) GPR156 variants and uses thereof
KR102493894B1 (ko) 인간화 tmprss 유전자를 갖는 설치류
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
US20080199480A1 (en) Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
CN1704478A (zh) 评估急性髓性白血病患者的方法
US6566061B1 (en) Identification of polymorphisms in the PCTG4 region of Xq13
KR20210116480A (ko) 기분 장애의 설치류 모델
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US20040171003A1 (en) Cancer-associated genes
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
US20040161759A1 (en) Test and model for inflammatory disease
JP2003259875A (ja) ヒト遺伝子の一塩基多型（４）
TW202313972A (zh) 新ｎｒｇ１融合物、融合接合處及檢測彼等之方法
CN114053413A (zh) 一种col4a4基因作为急性缺血性卒中治疗靶点的应用
US20020142381A1 (en) Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
JP2003180359A (ja) 新規遺伝子及びそれにコードされる蛋白質
CA2887830A1 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)